REVISED EDITION

Pharmacy-
Coordinated
Investigational
Drug Services

Edited by
Michael H. Stolar, Ph.D.
Director, Pharmacy Practice Research
International Health Information
Applications, Inc.
Washington, DC

In collaboration with
Thomas Gabriel, B.S., Manager
Pharmacy Investigational Drug Program
University of Wisconsin Hospital & Clinics
Madison, Wisconsin

Kathryn L. Grant, Pharm.D., Director
Drug Information & Poison Control Center
University of Wisconsin Hospital & Clinics
Madison, Wisconsin

Jim M. Koeller, M.S., Associate Clinical Professor
University of Texas Health Science Center
Oncology Clinical Specialist
Division of Clinical Oncology
Audie L. Murphy Memorial Veterans' Hospital
San Antonio, Texas

Published by
American Society of Hospital Pharmacists
4630 Montgomery Avenue
Bethesda, Maryland 20814
### Contents

**Preface** .................................................................................. V

**Acknowledgments** ............................................................... VI

**Part 1/Introduction** ................................................................. 1

Rationale and Concept of a Pharmacy-Coordinated Investigational
Drug Service ................................................................. 1

Goals and Objectives of the IDS ........................................ 1

Services and Responsibilities of the IDS ....................... 2

Benefits of the IDS .............................................................. 2

Objectives of this Manual and How to Use It ....................... 2

Suggested Readings ............................................................... 3

**Part 2/The Investigational Drug Study Process and
the Hospital Pharmacist** .................................................... 4

Overview of the Drug Research and Approval Process ............ 4

Preclinical Studies ............................................................... 5

Clinical Studies ................................................................. 6

Phase I Studies .................................................................. 6

Phase II Studies .................................................................. 7

Phase III Studies .................................................................. 7

Phase IV Studies/Postmarketing Surveillance ....................... 9

Prerequisites for Initiating and Conducting a Clinical Research
Study in an Institution ....................................................... 10

Institutional Review Board .................................................. 11

Informed Consent ............................................................... 12

Suggested Readings ............................................................... 16

**Part 3/Activities of the Investigational Drug Service** .......... 17

Basic Functions of the IDS ..................................................... 17

Distribution and Control of Investigational Drugs .................. 17

Procurement ...................................................................... 17

Storage, Inventory Control, Dispensing Records, and Audits ...... 19

Dispensing Investigational Drugs—Inpatient ......................... 22

Dispensing Investigational Drugs—Outpatient ....................... 23

Use of Investigational Drugs by Unauthorized Physicians
or for Unauthorized Patients .............................................. 26

Investigational Use of Marketed Drugs ................................. 26

Computerization of IDS Drug Distribution and
Control Functions .......................................................... 30

Disposal of Unused/Unusable Drugs ...................................... 30

Clinical Services ................................................................. 31

Patient Monitoring ............................................................. 31

Patient Education ................................................................ 32

Adverse Drug Reaction Reporting ....................................... 32

Staff Development/Education .............................................. 33

Research Activities ............................................................. 34

Identifying Research Needs, Capabilities, and Personnel ........ 34

Research Proposals ........................................................... 34

Research Protocols ........................................................... 37

Locating Sources of Research Support .................................. 39

Randomization and Blinding ................................................ 41

Data Collection and Dissemination of Results ....................... 42

Pharmaceutical Research ..................................................... 42

Phase I and II Studies and the IDS ....................................... 43

IDS as Study Sponsor or Investigator .................................... 43
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Management of Clinical Studies</td>
<td>43</td>
</tr>
<tr>
<td>Standard Operating Procedures</td>
<td>44</td>
</tr>
<tr>
<td>Study Coordinator or Manager</td>
<td>44</td>
</tr>
<tr>
<td>Financial Aspects</td>
<td>44</td>
</tr>
<tr>
<td>Management of the IDS</td>
<td>45</td>
</tr>
<tr>
<td>IDS Resource Requirements</td>
<td>45</td>
</tr>
<tr>
<td>Daily Management</td>
<td>45</td>
</tr>
<tr>
<td>Establishing an IDS</td>
<td>47</td>
</tr>
<tr>
<td>Benefits to Hospital Administration</td>
<td>47</td>
</tr>
<tr>
<td>Benefits to Nursing Staff</td>
<td>47</td>
</tr>
<tr>
<td>Benefits to Investigators</td>
<td>52</td>
</tr>
<tr>
<td>Benefits to Sponsors</td>
<td>52</td>
</tr>
<tr>
<td>Benefits to Patients</td>
<td>52</td>
</tr>
<tr>
<td>Suggested Readings</td>
<td>54</td>
</tr>
</tbody>
</table>

**Part 4/Appendices** ........................................................................................................... 55

Appendix 1. Notice of Claimed Investigational Exemption for a New Drug (FDA 1571) ........................................... 56
Appendix 2. Statement of Investigator—Clinical Pharmacology (FDA 1572) .......................................................... 59
Appendix 3. Statement of Investigator (FDA 1573) .............................................................. 61
Appendix 4. FDA Regulations on Institutional Review Boards (21 CFR 56) .......................................................... 63
Appendix 5. Additional Protections for Children Involved as Subjects in Research (Subpart D, Part 46 of 45 CFR) ............................. 69
Appendix 7. FDA Information Sheet: Non-Local IRB Review ................................................................. 78
Appendix 8. FDA Information Sheet: Cooperative Research ................................................................. 81
Appendix 9. FDA Bureau of Drugs Clinical Guidelines ........................................................................... 83
Appendix 10. FDA Information Sheet: Continuing Review .......................................................................... 84
Appendix 11. FDA Regulations on Informed Consent of Human Subjects ........................................................................... 88
Appendix 12. FDA Information Sheet: IRBs and Medical Devices ............................................................................. 90
Appendix 13. Example of a Pharmaceutical Manufacturer's Statement of Investigator's Obligations ................................................................. 94
Appendix 14. Instructions for the NCI Drug Accountability Record ........................................................................... 96